When most people hear the name Moderna, they immediately think of mRNA vaccines. But the company’s research has grown well beyond infectious diseases. Moderna is now using its mRNA technology to explore potential treatments for some of the most difficult medical challenges, including cancer and rare genetic disorders.
The concept behind mRNA medicine is relatively simple: mRNA carries temporary instructions that tell cells how to make particular proteins. Researchers can design those instructions for different medical purposes. In cancer, the goal may be to help the immune system recognize and attack tumor cells. In certain rare diseases, the goal is to help cells produce a protein that the body is unable to make properly.
Moderna’s current pipeline includes investigational programs in both oncology and rare diseases, showing how the company is trying to turn its mRNA platform into a broader therapeutic technology.
How Moderna Is Applying mRNA Beyond Vaccines
Traditional vaccines are only one possible use for mRNA. Moderna is exploring several therapeutic approaches, including cancer immunotherapy and systemic treatments for rare diseases.
The appeal of mRNA comes from its flexibility. Instead of permanently changing a person’s DNA, an mRNA medicine can provide cells with temporary biological instructions. Once those instructions are used and the mRNA breaks down, the effect can be designed to be temporary.
That flexibility gives researchers an opportunity to investigate treatments for diseases that have historically been difficult to address.
Moderna’s Growing Focus on Cancer Research
Cancer is one of the most important areas in Moderna’s current therapeutic strategy. The company is studying whether mRNA can help the immune system identify cancer cells more effectively.
One of the most closely watched programs is intismeran autogene (mRNA-4157), an investigational individualized neoantigen therapy being developed with Merck. The treatment is designed around information from an individual patient’s tumor, allowing researchers to create a personalized set of instructions intended to stimulate an immune response against tumor-specific targets.
This personalized approach is particularly interesting because cancer is not one single disease. Tumors can have very different genetic characteristics from one patient to another, and even cancers of the same type can behave differently.
Personalized Cancer Treatment
The idea behind an individualized cancer vaccine is to analyze a patient’s tumor and identify specific mutations that could potentially be recognized by the immune system.
Researchers can then use that information to design an mRNA-based treatment intended to train or stimulate immune cells to recognize those targets.
It is an ambitious concept because treatment becomes more closely connected to the biological characteristics of an individual patient’s cancer rather than relying entirely on a one-size-fits-all approach.
However, personalized treatment also creates practical challenges, including manufacturing speed, quality control, clinical logistics and cost.
Moderna Is Exploring More Than One Cancer Strategy
Moderna’s oncology pipeline is broader than personalized cancer vaccines. As of May 2026, its pipeline included intismeran autogene in several Phase 2 and Phase 3 cancer studies, along with investigational programs such as mRNA-4359, mRNA-4106, mRNA-4200 and mRNA-2808.
These programs are exploring different ways of using mRNA technology.
For example, mRNA-4359 is being investigated as a cancer antigen therapy for solid tumors. The approach is designed to encourage an immune response against selected cancer-associated targets. Early-stage research is still needed to determine how effective this strategy can be across different cancers.
Moderna is also studying mRNA approaches involving T-cell engagers and technologies intended to support cell therapies. This wider portfolio suggests the company is not relying on a single theory about how mRNA could be useful in cancer treatment.
Moving From Cancer Treatment Toward Prevention
Perhaps one of the most interesting developments is Moderna’s exploration of cancer prevention.
In June 2026, Moderna announced authorization for a Phase 1/2 study of mRNA-4194 for people with Lynch syndrome. Lynch syndrome is an inherited condition associated with an increased risk of developing certain cancers.
The investigational approach is intended to explore whether mRNA technology could stimulate the immune system against cancer-related targets before cancer develops. The study remains experimental, so it is too early to know whether this strategy will ultimately prevent cancer.
Still, the idea represents an important change in thinking: instead of waiting until cancer is diagnosed, researchers are investigating whether certain high-risk groups could potentially benefit from earlier intervention.
Moderna’s Work in Rare Diseases
Cancer is only half of the story. Moderna is also using mRNA technology to investigate rare diseases, particularly conditions involving problems with specific proteins or metabolic pathways.
Its current pipeline lists mRNA-3927 for propionic acidemia (PA) and mRNA-3705 for methylmalonic acidemia (MMA), both currently shown as Phase 2 programs.
These diseases are especially challenging because they can result from genetic changes that interfere with important metabolic processes.
Propionic Acidemia
Propionic acidemia is a rare inherited metabolic disorder that can cause serious health complications. Moderna is investigating mRNA-3927 as a potential therapy designed to provide cells with instructions related to the proteins involved in the affected metabolic pathway.
The program has advanced into clinical development, with Moderna reporting that it reached target enrollment in its registrational study.
The goal is not simply to manage symptoms. Researchers are exploring whether an mRNA-based treatment can address part of the underlying biological problem.
Methylmalonic Acidemia
Methylmalonic acidemia, or MMA, is another rare inherited metabolic disorder being studied by Moderna.
The company’s mRNA-3705 program is designed around the idea of helping cells produce a functional protein that is deficient because of the disease. Moderna has continued advancing the program and reported plans for registrational development.
This illustrates one of the most interesting possibilities of mRNA technology: rather than supplying a protein from outside the body, researchers are investigating whether cells themselves can temporarily be instructed to produce it.
Why Rare Disease Research Is So Challenging
Developing treatments for rare diseases is not easy.
Patient populations can be extremely small, making clinical trials difficult to organize. Some diseases also require long-term treatment, which means researchers must carefully evaluate safety, durability and the practical burden of repeated dosing.
For mRNA medicines, delivery is another major scientific challenge. Researchers need to make sure the mRNA reaches the appropriate cells and produces the intended biological effect without creating unacceptable side effects.
These challenges mean that promising laboratory results do not automatically translate into an approved treatment.
What Makes Moderna’s Approach Interesting?
The biggest advantage of Moderna’s platform may be its adaptability.
The same basic mRNA concept can potentially be redesigned for very different medical problems. In one case, it can be used to help the immune system recognize cancer-related targets. In another, it can be investigated as a way to help cells produce a missing protein.
Moderna describes its research strategy as covering different mRNA modalities, including cancer therapies and systemic intracellular therapeutics.
That platform-based approach could become increasingly valuable if researchers can demonstrate that lessons learned from one disease can accelerate development for another.
The Challenges Ahead
It is important to keep expectations realistic. Most of Moderna’s cancer and rare-disease therapies are still investigational. Clinical trials must establish safety and meaningful patient benefit before regulatory approval can occur.
Cancer treatment also involves complicated biology. A therapy that works for one tumor type or patient group may not work equally well for another.
For rare diseases, repeated dosing, delivery and long-term safety remain important questions.
Manufacturing personalized cancer treatments presents another challenge. A personalized therapy needs to move efficiently from tumor analysis to treatment production and administration.
So while the science is promising, there is still a considerable distance between an experimental mRNA treatment and a widely available medicine.
What the Future Could Mean for Patients
Moderna’s expansion into cancer and rare disease research shows how quickly mRNA technology is evolving.
In cancer, the company is investigating personalized neoantigen therapies, cancer antigen therapies and other immune-based approaches. In rare diseases, it is exploring whether mRNA can help cells produce proteins involved in important biological processes.
The long-term impact will depend on clinical results. If these programs demonstrate strong safety and effectiveness, mRNA could become more than a vaccine technology. It could become a flexible platform for developing medicines tailored to specific biological problems.
Final Thoughts
Moderna’s work in cancer and rare disease research represents an important next chapter for mRNA biotechnology.
The company’s cancer programs are exploring a more personalized relationship between a patient’s tumor biology and treatment, while its rare-disease programs are investigating whether cells can be temporarily instructed to produce proteins that are missing or defective.
There is no guarantee that every investigational program will succeed. But the research demonstrates how scientists are moving mRNA technology into areas where conventional approaches may not always provide enough answers.
For patients and researchers, the most exciting possibility is not simply a new drug. It is the potential for a more adaptable way of designing medicines—one that could eventually be customized to the biological needs of different diseases and individual patients.
Frequently Asked Questions
1. What is Moderna researching beyond vaccines?
Moderna is researching mRNA-based treatments for areas including cancer, rare genetic diseases, and other serious medical conditions.
2. How could Moderna’s mRNA technology help treat cancer?
Researchers are studying mRNA therapies that may help the immune system recognize and attack cancer cells, including personalized cancer vaccine approaches.
3. Which rare diseases is Moderna studying?
Moderna is investigating mRNA-based therapies for rare metabolic disorders such as propionic acidemia and methylmalonic acidemia.
4. Are Moderna’s cancer and rare disease treatments approved?
Many of Moderna’s cancer and rare-disease programs are still investigational and are being evaluated through clinical trials. Experimental treatments are not guaranteed to receive regulatory approval.
